Therapy for fungal diseases: opportunities and priorities

被引：247

作者：

Denning, David W. ^{[1
]}

Hope, William W. ^{[1
]}

机构：

[1] Univ Manchester, Univ S Manchester Hosp, Manchester Acad Hlth Sci Ctr, Sch Translat Med, Manchester M23 9LT, Lancs, England

来源：

TRENDS IN MICROBIOLOGY | 2010年 / 18卷 / 05期

关键词：

LIPOSOMAL AMPHOTERICIN-B; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; CLINICAL-PRACTICE GUIDELINES; RANDOMIZED CONTROLLED-TRIAL; HIGH-DOSE FLUCONAZOLE; CARE CANCER CENTER; DOUBLE-BLIND TRIAL; INVASIVE ASPERGILLOSIS; PULMONARY ASPERGILLOSIS; CRYPTOCOCCAL MENINGITIS;

D O I：

10.1016/j.tim.2010.02.004

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

This article provides a perspective on the current status of drug therapy for invasive fungal diseases, together with priorities for the future development of novel compounds. Key opportunities for new drugs include production of orally bioavailable agents for the treatment of invasive aspergillosis, invasive candidiasis, cryptococcal meningitis and mucosal and urinary Candida infections. Orally bioavailable agents for the treatment of chronic pulmonary and allergic aspergillosis are also required, as well as new potent drugs against a range of medically important moulds. Antifungal resistance is a problem in certain contexts, but is generally less of a problem than bacterial infections. Earlier and more complete mycological diagnosis and improvements in underlying risk estimation will improve outcomes. The limitations of the current antifungal agents and opportunities for new developments are discussed.

引用

页码：195 / 204

页数：10

共 100 条

[1]

Agarwal R, 2009, INT J TUBERC LUNG D, V13, P936

[2] Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1 [J].